Rishabh Jain, Medical Oncologist at AIIMS, shared on X:
“ESMO 2026 Cervical Cancer Guideline Update Several practice-relevant changes worth noting:
- Low-risk early disease: Simple hysterectomy + SLNB is now recommended for selected FIGO IA2–IB1 patients.
- LACC: Cisplatin-based CCRT + image-guided brachytherapy remains the backbone.
- Stage IIIA–IVA: Pembrolizumab + CCRT → maintenance pembrolizumab is recommended.
- INTERLACE strategy: Weekly carboplatin–paclitaxel induction may be considered when modern RT/brachytherapy techniques are unavailable.
- Metastatic disease: Treatment increasingly driven by PD-L1, prior immunotherapy and ADC options.
Cervical cancer management is rapidly moving toward less radical surgery early and more effective systemic intensification in advanced disease.”
Other articles featuring Rishabh Jain on OncoDaily.
